Follow Us On

Facebook  X  Linkedin  YouTube
 
 

‘Unsustainable’: Physicians, Lawsuit Challenge Medicare’s WISeR Prior Auth Experiment



When Matthew Crooks, MD, interventional pain specialist in Phoenix, first heard about Medicare’s new prior authorization (PA) program, he was optimistic about its goal of reducing unnecessary care and controlling costs.


But nearly 3 months in, the reality is much different. Medicare has denied payment for any epidural steroid injections since the rollout, even for procedures with valid authorization numbers, Crooks said.


“This system is completely nonfunctional and unsustainable, and we have been given no guidance to navigate it,” Crooks said.


Many physicians and medical societies have reported delays, denials, and communication breakdowns since WISeR — the Wasteful and Inappropriate Service Reduction program — launched on January 1 in select states.


Click here to read the full article.

Gabapentin, Pregabalin Tied to Higher Risks Early in Treatment

Drug poisoning rates rose, especially when used with other prescriptions

 

Key Takeaways


•  Gabapentin and pregabalin users had a higher incidence of drug poisoning, especially early in treatment.


•  Poisoning rates rose further when gabapentinoids were combined with benzodiazepines or opioids.


•  The study used a self-controlled case series approach to assess poisonings before and after gabapentinoids were prescribed.

People prescribed gabapentinoids -- gabapentin or pregabalin -- had a higher risk of drug poisoning soon after they started treatment, especially if they took benzodiazepines or opioids concurrently, a study of 17,000 U.K. primary care patients showed.


Compared with reference periods, the risk of hospitalization for drug poisoning rose during the first 4 weeks of gabapentinoid treatment, with an adjusted incidence rate ratio (aIRR) of 1.81 (95% CI 1.66-1.99, P<0.001), reported Kenneth Man, PhD, of the University College London, and co-authors.


Click here to read the full article.

Register Today for these

Upcoming ASIPP Workshops

 


Apply now for one of the following dates:


May 23 & June 27, 2026



  • ABIPP Part I

Four (4) hour virtual exam


  • ABIPP Path – Combined CCPM/ CSM Exam

For those with subspecialty in Pain Medicine

Two (2) hour virtual exam


  • ABIPP Competency Exam in IPM

For those without primary board certification

Two (2) hour virtual exam


  • ABIPP Competency Exam in Regenerative Medicine

Two (2) hour virtual exam


  • Controlled Substance Management Competency Exam

Two (2) hour virtual exam


  • Documentation, Coding, Compliance, Practice Management Competency Exam

Two (2) hour virtual exam


August 28, 2026


  • ABIPP Part II Practical Examination

Topics that will be covered:

Caudal epidural injections; Lumbar interlaminar epidural injections; Lumbar/sacral transforaminal epidural injections; Cervical epidural injections; Thoracic epidural injections; Lumbar/sacral medial branch and L5 dorsal ramus blocks; Cervical medial branch blocks; Thoracic medial branch blocks; Lumbar/sacral facet joint nerve radiofrequency neurolysis; Cervical medial branch radiofrequency neurolysis; Thoracic medial branch radiofrequency neurolysis; Sacroiliac joint injections; Cervical sympathetic blocks; Lumbar paravertebral sympathetic blocks; Intercostal nerve blocks; Lumbar discography; Celiac plexus blocks (not Splancnic nerve blocks); Percutaneous epidural adhesiolysis; Spinal cord stimulation lead placement

Exam Dates



Researchers, Advocates Welcome Executive Order on Psychedelics 



A new executive order directing federal agencies to increase researchers’ access to psychedelics for psychiatric conditions was hailed by scientists, clinicians, and advocates, who said it is a long-overdue acknowledgment of the compounds’ potential as a treatment for psychiatric illness.


Signed by President Donald J. Trump on April 18 in a White House ceremony, the order seeks to speed studies of such drugs as Lysergide (LSD), psilocybin, 3,4-methylenedioxymethamphetamine (MDMA), and ibogaine, all of which are classified as Schedule I controlled substances.


Trump’s action could lift existing legal roadblocks to psychedelic studies, allocate research funding to support the development of psychedelic-based therapeutics, and direct the FDA to provide National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designation.


Click here to read the full press release.

Physicians Beat AI Scribes on Clinical Note Quality, Study Shows

11 AI scribes were tested against doctors in VA trial

 

Key Takeaways


•  Clinical notes generated by artificial intelligence (AI) scored lower on quality than those prepared by humans in this cross-sectional study of five simulated primary care cases.


•  The largest difference in quality occurred in a case in which a clinician and patient discussed back pain amid background noise.


•  Though AI scribes have "emerged as a promising approach to alleviating documentation burden," the researchers said that "concerns remain about accuracy, completeness, and style."

Clinical notes generated by artificial intelligence (AI) scored lower on quality than those prepared by humans, a cross-sectional evaluation of five simulated primary care cases showed.


Notes were rated on 10 attributes (such as being accurate, thorough, organized, and comprehensive) using the modified Physician Documentation Quality Instrument (PDQI-9). The tool measures each attribute on a 5-point scale, with a maximum score of 50.


The largest difference in quality between AI and human notes occurred when a clinician and patient discussed back pain amid substantial background noise, with the human notes scoring 43.8, while AI scored just 20.3 (P≤0.001), Ashok Reddy, MD, MSc, of the Veterans Affairs Puget Sound Health Care System in Seattle, and colleagues reported in Annals of Internal Medicine and at the American College of Physicians meeting in San Francisco.


Click here to read the full article.

Our Sponsor

ASIPP is pleased to announce the launch of the Regenerative and Longevity Medicine Section!


This section reflects the growing importance of regenerative and longevity medicine—fields dedicated to restoring health, enhancing vitality, and extending the healthy years of life. From stem cell therapies and tissue engineering to gene therapy and orthobiologics, these disciplines are transforming the way we approach pain management and age-related decline.


Section membership offers:

  • Access to ASIPP’s physician database and future data registry
  • Opportunities for certification and continuing education
  • Section-exclusive resources and updates


Click here to apply.

No additional cost for ASIPP members!

ASIPP is proud to launch our Resident and Fellow Mentorship Program. This initiative is designed to connect trainees with experienced pain physicians to foster professional growth, provide guidance, and strengthen the future of our specialty.


Each mentor would be paired with one to two trainees, but can take more if interested. Trainees will be responsible for initiating introductions and arranging at least one to two video calls per year. These sessions will provide opportunities for mentees to seek advice on clinical decision-making, career planning, research opportunities, and professional development.


We believe that your experience, expertise, and insight can have a lasting impact on the next generation of pain physicians. By volunteering as a mentor, you will play a critical role in shaping the future of our field and ensuring that ASIPP continues to cultivate excellence in interventional pain medicine.


If you are interested in serving as a mentor, please confirm your participation by filling out the appropriate form below.

Midlife Migraines Tied to Higher Dementia Risk, 40-Year Study Suggests

Findings add to the evidence exploring whether migraines and dementia are connected



A large study spanning more than 40 years suggested that migraines in midlife were associated with a modest increase in the long-term risk of dementia.


Adults with migraines in midlife were slightly more likely to experience dementia later in life compared with those without migraine (HR 1.07, 95% CI 1.02-1.13), reported Pamela Rist, PhD, of Brigham and Women's Hospital in Boston, and colleagues in a poster session at the American Academy of Neurology annual meeting.


"Prior studies have mainly examined the association between late-life migraine and dementia," Rist noted. "This study adds to the body of evidence by suggesting that midlife migraine may also be associated with an increased risk of dementia," she told MedPage Today.


Click here to read the full article.




AMA: Physician burnout rates are falling, specialty gaps remain




New data from the American Medical Association (AMA) show physician burnout continuing to decline nationwide, but significant differences across medical specialties underscore the need for more targeted solutions within health systems.


In 2025, 41.9% of physicians reported experiencing at least one symptom of burnout—down from 43.2% in 2024 and 48.2% in 2023—reflecting steady progress in physician well-being also found in peer-reviewed research. However, AMA-exclusive data reveal that the burden of burnout is not shared equally by physicians across medicine.


“2025 marked another year of progress in reducing overall physician burnout levels,” said AMA President Bobby Mukkamala, MD. “This reflects broad gains in engagement, well-being, and perceived support across organizations. However, burnout varies widely by medical specialty, driven by differences in workload, administrative burden, clinical environment, staffing support, and the day-to-day realities of practice. Building effective, lasting solutions requires better understanding where physicians are struggling—and why.”


Click here to read the full article.

Our Sponsor

The Opportunity:

  • Well-established group seeking an interventional pain physician with pain fellowship training
  • Comprehensive interventional pain management program with physicians, nurse practitioners, and two Ambulatory Surgery Centers
  • Established interventional pain management practice with strong clinical and research focus
  • High-volume practice that is ethical and fully legally compliant
  • Research and publication opportunities available
  • Early and generous partnership opportunities in both the practice and ASC


The Community:

  • Excellent quality of life in a county of more than 60,000 residents, with a regional drawing area exceeding 200,000
  • High standard of living with abundant recreational and social opportunities
  • Strong public school system and a private parochial elementary school
  • Convenient location: approximately 2.5 hours to Nashville and St. Louis; 3 hours to Memphis, Louisville, and Lexington
  • Daily one-hour flights to major international hubs, including Chicago O’Hare and Houston, TX


Please email Cindy Jackson at cindy@thepainmd.com with your current CV to schedule an interview or to learn more about this practice.

 

We're excited to let you know that the new ASIPP Community, hosted by DocMatter, is now live!


The ASIPP Community on DocMatter will serve as a place for members to collaborate around clinical and research topics to advance the care of their interventional pain patients.


Click here to be a part of the conversation!

Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.


Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer review and quality control as any other scholarly journal.


Interested in becoming a member of the PMCR Editorial Board?

Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.


For more information or to submit your articles, click here.

We are excited to announce that Pain Medicine Case Reports (PMCR) journal (eISSN 2768-5152) has been accepted for inclusion in MEDLINE and PubMed, the prestigious bibliographic database of the U.S. National Library of Medicine. PMCR, a companion publication to the prestigious Pain Physician journal by ASIPP, joins its counterpart in achieving indexing in both MEDLINE and PubMed, marking ASIPP’s dual presence in these renowned databases.


The inclusion of PMCR journal in MEDLINE signifies a higher level of selectivity, as MEDLINE consists of the top 5,200 biomedical journals. This indexing also means that articles from PMCR will be searchable using NLM Medical Subject Headings (MeSH terms) and other metadata.


The selection for MEDLINE follows a rigorous evaluation process by reviewers from the Literature Selection Technical Review Committee (LSTRC). According to their criteria, the scientific quality of a journal’s content is the primary factor considered for indexing.


We extend our congratulations to the Pain Medicine Case Reports Editor-in-Chief, Deputy Editor-in-Chief, Journal Team, and Editorial Board for this achievement, which underscores the significance and excellence of this esteemed journal.

 

CASE REPORTS

Peripheral Nerve Stimulation for Intractable Neuropathic Foot Pain in Sickle Cell Disease: A Case Report Introducing a Novel Interventional Approach


Fei Cao, PhD, and Xiaofeng Yan, PhD

A Novel Multisite Peripheral Nerve Stimulation Approach for Chronic Hip Pain in Avascular Necrosis: A Case Report


Preston Rippe, DO, Marc Larsen Hallock, DO, and Christopher Mallard, MD

Simultaneous Closed-Loop Inceptiv Spinal Cord Stimulator and Bladder InterStim Implantation - A Case Report


Dylan W. Banks, MD, David S. Jevotovsky, MD, Mustafa Broachwala, DO, Amy Wang, MD, and Krishnan V. Chakravarthy, MD, PhD

 
 
 

OBSERVATIONAL STUDY

Retrospective Review of the Outcomes of 300 Minimally Invasive Lumbar Decompression® Cases: Real-World Outcomes Compared to Data in Published Literature


Christopher Zhang, Courtney Aronica, Sudhir A. Diwan, Christopher G. Gharibo, Gerard Abrahamsen, and Steve Aydin

RANDOMIZED CONTROLLED TRIALS

Does Oral Chromium Withstand Steroid Hyperglycemia in Postinterventional Ultrasound-guided Sacroiliac Joint Injections in Patients With Diabetes: A Double Blind Randomized Controlled Trial


Atef Mohamed Mahmoud, Ahmed Tarek Abd El Azim, Mohamed Ahmed Shawky, and Mohamed Ahmed Hamed

The Effects of Ultrasound-Guided Genicular Nerve Blocks Used with Local Anesthetics Alone or in Combination with Corticosteroids on Patients with Knee Osteoarthritis: A Placebo-Controlled Randomized Clinical Trial


Claudia de la Fuente-Escudero, Carla Sofia Den Heijer, Fatima N. Bebea Zamorano, Elia Perez-Fernandez, Mariano Tomas Florez-Garcia, Jose Martel Viliiagran, Javier Martinez Martin, and Cristina Duran-Carretero




ASIPP is in collaboration with Curi Medical Liability Program




Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices. 

 

Curi is a full-service advisory firm that serves physicians and their practices. Their valued advice is grounded in your priorities and elevated in your outcomes. They are driven by a deep understanding of your specific circumstances in medicine, business, and life. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary risk management CME activities, visit our website.



IMPORTANT UPDATE

SPRINT no longer classified as PNT 



SPR is happy to announce an important update regarding Humana Medicare Advantage. As of May 1, Humana is now recognizing SPRINT as a PNS therapy. Previously, SPRINT was categorized as PNT (Percutaneous Nerve Stimulation), which allowed denials on the grounds that the therapy fell outside the NCD.


Additional details are as follows:

Payer: Humana Medicare Advantage (click here to view policy)

Policy Title: Peripheral Nerve Stimulators

Policy changes: SPRINT no longer misclassified as PNT and is now appropriately classified as PNS. Humana is applying the Noridian Medicare LCD criteria to ALL PNS devices – Including SPRINT PNS!

Effective Date: 5/1/2025


Click here to view a PDF of the official policy update.

 

Group Purchasing Organization Offer Better Pricing and Creates Added Value


ASIPP has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for independent physicians. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.



Learn More


For updated information concerning tariffs on products, click here.

 
 

ASIPP, Fedora Healthcare Solutions Partnership


ASIPP offers our members the benefit of a unique revenue cycle management/ billing service.



We have received a tremendous amount of interest in the ASIPP billing and coding program.




Click here to learn more about the negotiated rate for practices and more!

Like and Follow ASIPP® on Facebook, X, LinkedIn,

and YouTube for the most up-to-date news

related to you, your practice, and your patients!